Aptamer binding footprints discriminate α-synuclein fibrillar polymorphs from different synucleinopathies

• Published in: Nucleic acids research Vol. 52; no. 14; pp. 8072 - 8085
• Main Authors: Bouvier-Müller, Alix, Fourmy, Deborah, Fenyi, Alexis, Bousset, Luc, Melki, Ronald, Ducongé, Frédéric
• Format: Journal Article
• Language: English
• Published: Oxford University Press 12.08.2024
• Subjects: Biochemistry, Molecular Biology; Biodiversity; Biotechnology; Chemical Biology and Nucleic Acid Chemistry; Life Sciences; Molecular biology; Populations and Evolution; Quantitative Methods; aptamer; Synucleinopathies; SELEX
• ISSN: 0305-1048; 1362-4962; 1362-4962
• DOI: 10.1093/nar/gkae544

Abstract Synucleinopathies, including dementia with Lewy bodies (DLB), Parkinson's disease (PD), and multiple system atrophy (MSA), are characterized by the presence of α-synuclein (α-syn) aggregates in the central nervous system. Recent evidence suggests that the heterogeneity of synucleinopathies may be partly explained by the fact that patients may have different α-syn fibrillar polymorphs with structural differences. In this study, we identify nuclease resistant 2′fluoro-pyrimidine RNA aptamers that can differentially bind to structurally distinct α-syn fibrillar polymorphs. Moreover, we introduce a method, AptaFOOT-Seq, designed to rapidly assess the affinity of a mixture of these aptamers for different α-SYN fibrillar polymorphs using next-generation sequencing. Our findings reveal that the binding behavior of aptamers can be very different when they are tested separately or in the presence of other aptamers. In this case, competition and cooperation can occur, providing a higher level of information, which can be exploited to obtain specific ‘footprints’ for different α-Syn fibrillar polymorphs. Notably, these footprints can distinguish polymorphs obtained from patients with PD, DLB or MSA. This result suggests that aptaFOOT-Seq could be used for the detection of misfolded or abnormal protein conformations to improve the diagnosis of synucleinopathies. Graphical Abstract Graphical Abstract